Details for New Drug Application (NDA): 205414
✉ Email this page to a colleague
The generic ingredient in FEBUXOSTAT is febuxostat. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the febuxostat profile page.
Summary for 205414
| Tradename: | FEBUXOSTAT |
| Applicant: | Hikma |
| Ingredient: | febuxostat |
| Patents: | 0 |
Pharmacology for NDA: 205414
| Mechanism of Action | Xanthine Oxidase Inhibitors |
Medical Subject Heading (MeSH) Categories for 205414
Suppliers and Packaging for NDA: 205414
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FEBUXOSTAT | febuxostat | TABLET;ORAL | 205414 | ANDA | Hikma Pharmaceuticals USA Inc | 0054-0413 | 0054-0413-13 | 30 TABLET in 1 BOTTLE (0054-0413-13) |
| FEBUXOSTAT | febuxostat | TABLET;ORAL | 205414 | ANDA | Hikma Pharmaceuticals USA Inc | 0054-0414 | 0054-0414-13 | 30 TABLET in 1 BOTTLE (0054-0414-13) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
| Approval Date: | Oct 15, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
| Approval Date: | Oct 15, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
